Literature DB >> 3110472

Blood ammonia level during valproic acid therapy.

T Kugoh, M Yamamoto, K Hosokawa.   

Abstract

We determined the blood ammonia level of epileptic patients in relation to valproic acid (VPA) therapy. A total determination of 256 specimens obtained from 174 cases were analyzed. The materials were assigned to the following three treatment groups: (a) VPA-monotherapy, (b) VPA-polytherapy and (c) non-administration of VPA. The distribution ranges of the blood ammonia level (micrograms/dl) were 40.5, 56.6 and 40.7 in mean, respectively. The VPA-polytherapy group showed a significantly higher level compared with the other two groups. On the other hand, the latter two groups showed no difference. There was a positive relationship between the blood ammonia and VPA serum levels with statistical significance. In conclusion, a critical factor causing hyperammonemia seemed to be the multiple use of antiepileptic drugs including VPA.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3110472     DOI: 10.1111/j.1440-1819.1986.tb03182.x

Source DB:  PubMed          Journal:  Jpn J Psychiatry Neurol        ISSN: 0912-2036


  5 in total

1.  Valproic acid-associated encephalopathy.

Authors:  G L Jones; F Matsuo; J R Baringer; W H Reichert
Journal:  West J Med       Date:  1990-08

2.  Risk factors and outcome of hyperammonaemia in people with epilepsy.

Authors:  Umesh Vivekananda; Simona Balestrini; Angeliki Vakrinou; Elaine Murphy; Sanjay M Sisodiya
Journal:  J Neurol       Date:  2022-07-30       Impact factor: 6.682

3.  Differential ammonia decay kinetics indicates more than one concurrent etiological mechanism for symptomatic hyperammonemia caused by valproate overdose.

Authors:  Deb Kumar Mojumder; Radhames Ramos De Oleo
Journal:  Indian J Pharmacol       Date:  2014 May-Jun       Impact factor: 1.200

4.  Blood Levels of Ammonia and Carnitine in Patients Treated with Valproic Acid: A Meta-analysis.

Authors:  Saaya Yokoyama; Norio Sugawara; Kazushi Maruo; Norio Yasui-Furukori; Kazutaka Shimoda
Journal:  Clin Psychopharmacol Neurosci       Date:  2022-08-31       Impact factor: 3.731

5.  Risk factors of hyperammonemia in patients with epilepsy under valproic acid therapy.

Authors:  Yu-Lung Tseng; Chi-Ren Huang; Chih-Hsiang Lin; Yan-Ting Lu; Cheng-Hsien Lu; Nai-Ching Chen; Chiung-Chih Chang; Wen-Neng Chang; Yao-Chung Chuang
Journal:  Medicine (Baltimore)       Date:  2014-09       Impact factor: 1.889

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.